GLP-1s and Pregnancy, PCOS, and Fertility: What the FDA Labels and the Trial Evidence Actually Say

GLP-1 weight loss drugs are contraindicated in pregnancy and the FDA labels for Wegovy, Ozempic, Zepbound, Mounjaro, and Foundayo all recommend discontinuation before planned conception — Wegovy specifically says at least 2 months before a planned pregnancy [1, 2, 6]. But the women's health story is more nuanced than that headline. GLP-1-induced weight loss in PCOS patients consistently improves menstrual regularity, reduces androgen levels, and the most-cited fertility study (Salamun et al., European Journal of Endocrinology 2018, PMID 29703793) showed that pre-conception liraglutide therapy improved IVF pregnancy rates in obese PCOS women beyond what metformin alone achieved [3]. This article walks through the verified FDA labels, the published PCOS evidence, the contraception interaction during dose escalation that the labels specifically warn about, and how to think about GLP-1 use through the family-planning timeline. This is the highest-YMYL category we publish — every clinical decision in this space belongs between you and your prescriber.

The pregnancy contraindication: what each FDA label actually says

Verified directly from each FDA prescribing information Section 8.1 (Pregnancy) [1, 2, 6]:

Wegovy and Ozempic (semaglutide)

The Wegovy label says: “Based on animal reproduction studies, there may be potential risks to the fetus from exposure to semaglutide during pregnancy... Weight loss offers no benefit to a pregnant patient and may cause fetal harm... Discontinue WEGOVY in pregnant patients.” The label specifies discontinuation at least 2 months before a planned pregnancy, which reflects the long elimination half-life of semaglutide (approximately 7 days — see our how long does GLP-1 take to work guide for the full PK explanation).

Animal reproduction findings: embryofetal mortality, structural abnormalities, and growth alterations in rats at clinically relevant exposures; early pregnancy losses and structural abnormalities in rabbits and primates [1].

Pregnancy registry: Novo Nordisk maintains a registry at 1-877-390-2760 or wegovypregnancyregistry.com [7]. Patients who become pregnant on Wegovy or Ozempic should report the exposure to the registry to help characterize outcomes.

Note: the FDA replaced the old A/B/C/D/X pregnancy categories in 2015 with narrative summaries, so neither Wegovy nor any other modern GLP-1 has a single-letter category. The narrative language is the operative guidance.

Zepbound and Mounjaro (tirzepatide)

The Zepbound label uses similar language: “Available data are insufficient to evaluate for drug-related risk of major birth defects, miscarriage, or adverse maternal outcomes... Weight loss is not recommended during pregnancy” [2]. Animal data show fetal growth reductions and abnormalities at clinical exposures in rats.

The Zepbound label is somewhat less specific than Wegovy about how many months before conception to discontinue — it doesn't state the explicit 2-month rule. Most clinicians extrapolate from the tirzepatide half-life (~5 days) and apply a similar 4-8 week pre- conception washout in practice.

Pregnancy registry: Eli Lilly at 1-800-LillyRx (1-800-545-5979).

Foundayo (orforglipron)

The new oral orforglipron has a slightly different animal reproduction profile than the injectable peptides — animal studies were not active in rats and rabbits at clinical exposures. Only primate data are relevant, and at sub-clinical exposures no adverse effects were noted [6]. However, the FDA label still treats Foundayo as contraindicated in pregnancy because human data is insufficient.

Foundayo has a unique label warning relevant to women of reproductive age: oral contraceptive efficacy may be reduced during dose escalation due to slowed gastric absorption. The label recommends a backup contraception method (barrier or non-oral hormonal) for 30 days after starting Foundayo and 30 days after each dose increase [6]. We expand on this in the contraception section below.

Contraception interaction with oral birth control

All injectable GLP-1s (semaglutide, tirzepatide, orforglipron) slow gastric emptying. Oral medications taken at the same time can have altered absorption, and the FDA labels specifically address oral contraceptives for several of the drugs [1, 2, 6].

The Wegovy and Zepbound labels both recommend that women using oral contraceptives consider an alternative contraceptive method or a non-oral hormonal contraceptive for the duration of dose escalation, because absorption may be unpredictable during the GI-adaptation phase. The Foundayo label is the most specific: backup contraception for 30 days after start and 30 days after each dose increase.

Practical takeaway: if you are sexually active and rely on oral contraceptives, talk to your prescriber about adding a backup method (condoms, IUD, implant) during the first 16-20 weeks of GLP-1 therapy and during any future dose changes.

PCOS: the published trial evidence

Polycystic ovary syndrome (PCOS) is the most common cause of female anovulatory infertility and is strongly associated with obesity and insulin resistance. PCOS-related infertility and menstrual irregularity often improve with weight loss, and several randomized trials have specifically tested GLP-1 therapy in this population.

The most-cited PCOS RCT for fertility outcomes is Salamun et al., European Journal of Endocrinology 2018 (PMID 29703793) [3]. Verified study details:

• n=28 infertile obese PCOS women (mean age 31 ± 4.75 years, mean BMI 36.7 ± 3.5) with prior poor response to first-line reproductive treatments
• Intervention: liraglutide 1.2 mg daily + metformin (combination arm) vs metformin alone (control arm) for 12 weeks pre-conception
• Result: Pre-conception liraglutide was superior to metformin alone in increasing pregnancy rates per embryo transfer AND in cumulative pregnancy rates, even though weight loss was similar between arms. The authors interpreted this as evidence that GLP-1 therapy may have direct benefits on the hypothalamic-pituitary- ovarian axis beyond weight loss alone.

A second RCT — Jensterle et al., BMC Endocrine Disorders 2017 (PMID 28479118) [4] — randomized n=72 women with obese PCOS to liraglutide regimens for 26 weeks. The trial reported improved menstrual bleeding patterns, decreased free testosterone, and a trend toward lower ovarian volume.

A 2024 meta-analysis of 4 RCTs (176 participants) of semaglutide and tirzepatide in PCOS reported:

• Tirzepatide: mean weight reduction −17.60 kg
• Semaglutide: mean weight reduction −11.85 kg
• Both produced reductions in waist circumference, BMI, triglycerides, and total testosterone

Important caveat: none of the GLP-1 drugs — semaglutide, tirzepatide, orforglipron — list PCOS as an FDA-approved indication. All PCOS use is off-label. Off-label prescribing is legal and routine in clinical practice, but it means the FDA has not formally evaluated these drugs for PCOS efficacy or safety.

The “GLP-1 babies” phenomenon

Anecdotal reports from fertility clinics describe a pattern where women with previously documented obesity-related anovulation conceive unexpectedly on GLP-1 therapy — sometimes referred to colloquially as “GLP-1 babies.” The mechanism is plausible: 5-10% body weight loss is well-documented to restore ovulation in obesity- associated anovulatory infertility, and GLP-1 therapy reliably produces that magnitude of weight loss within 12-20 weeks.

Beyond the indirect weight-loss effect, the Salamun 2018 trial [3] suggests there may be additional direct GLP-1 effects on the HPO axis (LH secretion, ovarian morphology, endometrial receptivity) — but most of this evidence remains preclinical.

The clinical implication: women on GLP-1 therapy who do not want to become pregnant must use reliable contraception, even if they had irregular cycles or documented infertility before starting the drug. Restored fertility is one of the documented secondary effects of weight loss in this population, and the FDA-recommended pregnancy washout period exists for a reason.

ACOG guidance on GLP-1s before and during pregnancy

ACOG (American College of Obstetricians and Gynecologists) Practice Bulletin No. 230 on Obesity in Pregnancy [5] addresses pre-pregnancy weight management broadly but does not provide a dedicated GLP-1-specific committee opinion as of April 2026. Available ACOG guidance recommends general pre-pregnancy BMI optimization and notes that even modest weight loss (4.5 kg) before conception decreases gestational diabetes risk by approximately 40%.

ACOG has not published a position statement specifically endorsing or restricting GLP-1 use beyond what the FDA labels already state.

Lactation: what the labels say

The FDA labels for Wegovy, Zepbound, and Foundayo all state that there are no data on the presence of the drug in human milk, the effects on the breastfed infant, or the effects on milk production [1, 2, 6]. Animal data on lactation are limited.

The labels recommend weighing the developmental and health benefits of breastfeeding against the mother's clinical need for the medication and any potential adverse effects on the breastfed infant from the drug. In practice, most prescribers do not recommend resuming GLP-1 therapy while actively breastfeeding given the absence of data, but this is a clinical judgment call that belongs with your obstetrician and pediatrician.

Egg freezing and IVF cycles: what to do with your GLP-1

Patients pursuing egg freezing or IVF should plan their GLP-1 timing around the procedure timeline:

• Before cycle start: Discontinue at least 2 months before conception (per the Wegovy label) — which for IVF means at least 2 months before embryo transfer.
• During stimulation and egg retrieval: Most reproductive endocrinologists are conservative and recommend the patient be off the GLP-1 throughout the stimulation cycle to avoid any unknown effects on oocyte quality. ASRM has not published a formal statement specific to GLP-1s, but the conservative default in most fertility clinics is “off the drug before the cycle.”
• After successful pregnancy: Stay off throughout pregnancy and (per most clinical practice) not resume during lactation.
• Pre-conception weight optimization: If your goal is to lose weight before conceiving to reduce maternal and fetal risk, work backwards from your target conception date by at least 4-6 months — 2-4 months on GLP-1 therapy followed by the 2-month pre-conception washout.

Practical decision framework

1. Are you actively trying to conceive? Discontinue GLP-1 at least 2 months before your planned conception date. Use the washout period to optimize dietary patterns and lifestyle that you can sustain through pregnancy without the drug.
2. Could you become pregnant unexpectedly? Use reliable contraception throughout GLP-1 therapy. During dose escalation specifically, add a backup method (barrier, IUD, implant) because oral contraceptive absorption may be reduced.
3. Do you have PCOS and want to conceive? Talk to your reproductive endocrinologist about a pre-conception GLP-1 protocol. The Salamun 2018 evidence [3] suggests this can improve IVF outcomes in selected patients, even though PCOS is not an FDA-approved indication.
4. Are you breastfeeding? Most prescribers do not recommend GLP-1 therapy during active breastfeeding due to absence of human milk safety data. Discuss with your obstetrician and pediatrician.
5. Did you become pregnant unexpectedly while on GLP-1 therapy? Stop the drug immediately and contact your obstetrician. Report the exposure to the manufacturer's pregnancy registry [7] so the field can characterize outcomes. Most exposed pregnancies in published case series have proceeded normally, but the data are limited and the FDA label is clear about discontinuation.

Important disclaimer

This article is the highest-stakes YMYL category we publish. It is educational and reflects what the published FDA prescribing information and primary clinical literature say as of April 2026. It is not a substitute for individual medical advice. Pregnancy, fertility, and contraception decisions in the context of GLP-1 therapy belong between you and your obstetrician, reproductive endocrinologist, and prescriber. Weight Loss Rankings does not provide medical advice, diagnosis, or treatment recommendations.

Related research and tools

For the broader weight loss trial data behind GLP-1 therapy, see our pricing index and weight loss calculator. For the muscle mass preservation strategy that matters especially in pre-conception weight loss, see our muscle mass deep-dive. For the discontinuation rebound data that's especially relevant during the pre-pregnancy washout, see our STEP-4 post-discontinuation review. For the broader side-effect profile that includes some women's-health-relevant effects, see our fatigue + hair loss + duration guide.